Multimorbidity in older patients creates a challenge because you're dealing with multiple diseases and multiple medications, explained Michael Steinman, MD, professor of medicine, University of California, San Diego.
Multimorbidity in older patients creates a challenge because you're dealing with multiple diseases and multiple medications, explained Michael Steinman, MD, professor of medicine, University of California, San Diego.
Transcript
Why are medication management strategies particularly important for older patients?
One of the issues with older patients is the presence of multimorbidity, so the challenge has become that much more complex because we’re not just dealing with a single disease, were dealing with multiple diseases and thinking about the interaction of all of those diseases, including the multiple medications a patient may be taking. They might make sense for one disease at a time, but when you add up all of the diseases and a patient ends up taking 18 medications, 9 of which are interacting with each other, and the patient can’t pay for their electric bill because they’re spending all their money on medications, that’s a problem.
So, being attentive the unique needs that arise from the presence of multimorbidity and thinking holistically about the patient and how to optimize their medication regimen in a way that makes sense for the person, not just the individual disease, is critical.
Are there challenges with trying to reach and engage these patients?
I think there’s a lot of variability in what strategies work for different patients. For example, if a strategy is just focused on getting patients to remember to take their medications more, that could be really useful for patients whose primary problem is just they forget to take their medications and having improved strategies for helping them, for example, with medication organizers or reminders. But, just to build on that example, a lot of nonadherence isn’t due to forgetting, it’s due to patients not thinking their medication is useful, not understanding why they’re taking it, or having real or perceived side effects and not wanting to take the medicine as a result.
Again, we need to be patient-centered on how we approach these things and really understanding what’s going on in the patient’s mind, why they’re acting or not acting a certain why, what’s going on in the prescriber’s mind, why they’re acting or not acting in a certain way, and addressing those levers accordingly.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More